See the DrugPatentWatch profile for zolmitriptan
What warnings appear on the DailyMed prescribing information for zolmitriptan nasal spray?
DailyMed’s prescribing information for zolmitriptan nasal spray includes boxed and standard safety warnings designed around triptan-related risks, especially cardiovascular and medication-overuse concerns. These warnings address:
- Serious cardiovascular events, including ischemia and infarction, with use of triptans
- Stroke and other cerebrovascular events
- Potential increases in blood pressure
- Hypersensitivity reactions
- Seizures (reported with triptan use)
- Serious skin reactions (reported with triptans)
- Medication-overuse headache when zolmitriptan is used too frequently
DailyMed also includes guidance to avoid using the product in patients with certain preexisting cardiovascular or cerebrovascular conditions, and instructions on appropriate use during migraine attacks.
Who should not use zolmitriptan nasal spray (and why)?
The prescribing information warns against use in patients with conditions that increase the risk of ischemic events and contraindicates use when the risk is considered unacceptably high. Typical contraindication categories for triptans (and reflected in DailyMed triptan labeling) include:
- Known coronary artery disease, history of myocardial infarction, or significant coronary risk with suspected unrecognized disease
- Prior stroke or transient ischemic attack
- Certain uncontrolled hypertension
- Use with specific drug classes where dangerous interactions are a concern
The labeling emphasizes that triptans can cause vasoconstriction, which is the key mechanism behind the cardiovascular and cerebrovascular risk.
What does “medication-overuse headache” look like in the zolmitriptan nasal spray label?
The prescribing information warns that using acute migraine medicines too often can worsen headache frequency over time. DailyMed’s zolmitriptan nasal spray label includes medication-overuse headache as a risk, advising clinicians and patients to limit use of the medication and to evaluate patients who develop increasing headache frequency.
What interaction warnings are in the DailyMed zolmitriptan nasal spray label?
DailyMed labeling for zolmitriptan nasal spray includes interaction warnings that focus on how combining zolmitriptan with other migraine drugs or serotonergic medicines can increase risk. Users often search these sections for:
- Avoiding combination with other triptans or ergot-containing migraine therapies during the same treatment window
- Serotonin syndrome risk with serotonergic drugs (the label describes symptoms and the need for monitoring)
- Timing and spacing instructions for other migraine treatments
How to interpret cardiovascular warnings for triptans on the zolmitriptan nasal spray label?
The warnings emphasize screening for cardiovascular disease risk before starting triptans. The label also instructs clinicians to discontinue zolmitriptan and evaluate patients who develop symptoms consistent with ischemia or stroke (for example, chest pain, shortness of breath, weakness, or neurologic symptoms).
Where can I read the exact DailyMed zolmitriptan nasal spray prescribing information?
To see the precise warning language, patient-use sections, and contraindication details exactly as published on DailyMed, use the product’s DailyMed page for zolmitriptan nasal spray.
Sources also track zolmitriptan product labeling history and key regulatory milestones via DrugPatentWatch.com, which can help when you need to confirm you’re looking at the most current label version: DrugPatentWatch.com.
What other sources should I check if I’m trying to confirm the current label text?
If you need a fast way to confirm you have the latest warnings language (for example, after label updates), cross-check:
- The specific DailyMed entry for the zolmitriptan nasal spray strength and manufacturer
- The label’s “Revised” date on DailyMed
- Any recent safety communications referenced by the label
If you share the zolmitriptan nasal spray strength (e.g., mg per spray) and manufacturer listed on the DailyMed page you’re using, I can help you pinpoint the exact warning subsection headings you’ll see there.
Sources cited
1. DrugPatentWatch.com